Skip to main content
IDYA logo

IDYA · IDEAYA Biosciences, Inc. · Documents

Track IDYA — free
$25.56 -0.61 (-2.33%) At close · Nov 20 Q4 2021 earnings call transcript
Market Cap
$2.47B
Shares
96.69M
Volume · Nov 20 1.11M Avg daily vol (3M) 932.53K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $218.71M up 3024.4% 10-K filed Feb 17, 2026 Quarterly report FY2026 Q3 Revenue $10.24M down 95.1% 10-Q filed Nov 3, 2026 Latest results Darovasertib NDA submitted; OptimUM-010 closure targets $100-125 million savings 8-K filed Nov 3, 2026 Earnings call Q4 2021 earnings call Held Mar 15, 2022
2026
Nov 16
Investor event
Rolling NDA filed; registrational trials planned

IDEA Biosciences filed its first rolling NDA for derovacertib in the third quarter and anticipates acceptance in the first half of next year. It plans to start two registrational phase three studies by the end of the year.

6 source passages
Chief Executive Officer of IDEA Biosciences here, Ujira Hata We filed our first NDA Yes, so the NDA has been filed. We noted that that happened in the third quarter. That was also filed under RTOR, so a rolling review submission process of the NDA. We do believe derovacertib is relevant, irrespective of HLA-A2 status. So that is how we did proceed with the NDA filing with that specific mindset in place. So at the time of NDA acceptance, we do anticipate it will be likely in that first half of next year timeframe. our plan to start two registrational phase three studies by the end of the year Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Darovasertib combination NDA submitted for metastatic uveal melanoma

IDEAYA Biosciences submitted an NDA to the FDA for the darovasertib combination in metastatic uveal melanoma, stopped enrollment in OptimUM-010, and reported approximately $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026.

Revenue $10.24M ▼ 95.1% Net loss $125.75M Diluted EPS -$1.22
Read from the MD&A section
4 source passages
We are developing darovasertib for uveal melanoma (UM), a rare, aggressive form of ocular cancer, in both the metastatic and pre-metastatic settings of UM, as described below. During the third quarter, we successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program to support a potential U.S. approval of the darovasertib combination in mUM. Due to ongoing site activation and enrollment challenges, we have decided to stop enrollment and close the Phase 3 OptimUM-010 trial. As of September 30, 2026, we had cash, cash equivalents and marketable securities of approximately $1.15 billion, consisting primarily of money market funds, U.S. government securities, commercial paper and corporate bonds. Open the document at this passage
Nov 3
Current report 8-K
Darovasertib NDA submitted; OptimUM-010 closure targets $100-125 million savings

IDEAYA Biosciences completed its darovasertib NDA submission, stopped enrollment in OptimUM-010 to save $100-125 million, and reported a $125.7 million net loss with $1.15 billion in cash and marketable securities at September 30, 2026.

Financial results
4 source passages
During the third quarter IDEAYA successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to support a potential U.S. approval of the darovasertib combination in mUM under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program. Due to ongoing site activation and enrollment challenges, IDEAYA has decided to stop enrollment and close the Phase 3 OptimUM-010 trial. This is expected to result in estimated cost savings of $100-125 million that the company will reallocate towards other high-value programs in its pipeline, including potential registrational trials for IDE849 and IDE892. As of September 30, 2026, IDEAYA had cash, cash equivalents and marketable securities of approximately $1.15 billion, compared to $1.24 billion as of June 30, 2026. The net loss for the three months ended September 30, 2026, was $125.7 million compared to the net loss of $112.5 million for the three months ended June 30, 2026. Open the document at this passage
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $8.86M Net loss $112.45M Diluted EPS -$1.22
Jun 10
Current report 8-K Events of Jun 8
Other events AI summary on its way
Jun 3
Current report 8-K
Other events AI summary on its way
May 5
Current report 8-K
Other events AI summary on its way
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $6.56M Net loss $98.54M Diluted EPS -$1.11
Apr 29
Proxy statement DEF 14A Meeting Jun 16, 2026
Proxy statement AI summary on its way
Apr 13
Current report 8-K
Other events AI summary on its way
Apr 9
Current report 8-K Events of Apr 8
Other events AI summary on its way
Feb 17
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $218.71M ▲ 3024.4% Net loss $113.7M Diluted EPS -$1.28
Jan 12
Current report 8-K Events of Jan 11
Other events AI summary on its way
2025
Feb 18
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $7M ▼ 70.1% Net loss $274.48M Diluted EPS -$3.36
2024
Showing 1–50 of 152 documents
Key facts CIK 1676725 CUSIP 45166A102 13F (30d) 297 filings 263 filers Visit website Investor relations